Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers
Top Cited Papers
Open Access
- 1 August 2005
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 202 (3) , 379-386
- https://doi.org/10.1084/jem.20040613
Abstract
Stem cell transplantation is used widely in the management of a range of diseases of the hemopoietic system. Patients are immunosuppressed profoundly in the early posttransplant period, and reactivation of cytomegalovirus (CMV) remains a significant cause of morbidity and mortality. Adoptive transfer of donor-derived CMV-specific CD8+ T cell clones has been shown to reduce the rate of viral reactivation; however, the complexity of this approach severely limits its clinical application. We have purified CMV-specific CD8+ T cells from the blood of stem cell transplant donors using staining with HLA–peptide tetramers followed by selection with magnetic beads. CMV-specific CD8+ cells were infused directly into nine patients within 4 h of selection. Median cell dosage was 8.6 × 103/kg with a purity of 98% of all T cells. CMV-specific CD8+ T cells became detectable in all patients within 10 d of infusion, and TCR clonotype analysis showed persistence of infused cells in two patients studied. CMV viremia was reduced in every case and eight patients cleared the infection, including one patient who had a prolonged history of CMV infection that was refractory to antiviral therapy. This novel approach to adoptive transfer has considerable potential for antigen-specific T cell therapy.Keywords
This publication has 21 references indexed in Scilit:
- Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell linesThe Lancet, 2003
- Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cellsThe Lancet, 2002
- Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapyBlood, 2002
- Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH (± fludarabine) conditioning combined with post-transplant donor-lymphocyte infusionCytotherapy, 2001
- PLASMA POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS DNA AFTER ALLOGENEIC MARROW TRANSPLANTATIONTransplantation, 1997
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytesNature Medicine, 1996
- Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the DonorNew England Journal of Medicine, 1995
- Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992